3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how ...
Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
House GOP charts roadmap to 'Make America Healthy Again,' cites healthcare system impact on 'national defense'
Texas, on Wednesday published a 47-page report titled “The Case for Healthcare Freedom" as a roadmap to "Make American ...
The FDA is about to make weight-loss drugs a lot harder to get
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Hosted on MSN20h
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
24/7 Wall St20h
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider
Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...
FierceBiotech22h
Novo Nordisk gets BACH1, inking IMMvention deal to orchestrate attack on sickle cell disease
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
ncbiotech.org22h
IMMvention Therapeutix to collaborate with Novo Nordisk on oral therapies for sickle cell, other chronic diseases
IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...